Colistin
Colistin is a pharmaceutical drug with 32 clinical trials. Currently 2 active trials ongoing. Historical success rate of 86.7%.
Success Metrics
Based on 13 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
3
Mid Stage
24
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
86.7%
13 of 15 finished
13.3%
2 ended early
2
trials recruiting
32
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Colistin Versus Colistin Combined With Cefoperazone-sulbactam for Multiresistant Acinetobactor Baumannii Ventilator-associated Pneumonia Treatment
Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy
Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii
Comparative Study of Secondary Prophylaxis for SBP
Clinical Trials (32)
Colistin Versus Colistin Combined With Cefoperazone-sulbactam for Multiresistant Acinetobactor Baumannii Ventilator-associated Pneumonia Treatment
Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy
Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii
Comparative Study of Secondary Prophylaxis for SBP
Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections
Pharmacokinetics of Colistin in Critically Ill Patients With Extracorporeal Membrane Oxygenation
The Effect of Curcumin Against Colistin-induced Nephrotoxicity
Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
Aerosolized Versus Intravenous Colistin-based Antimicrobial Regimens in Hospitalized COVID-19 Patients With Bacterial Coinfection: A Randomized Controlled Trial
Efficacy of Colistin Monotherapy Versus Colistin Plus Minocycline for Carbapenem-Resistant A. Baumannii Infection
Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients
Colistin Intravenous Administration in Critically Ill Patients Suffering From Hospital Infections Caused by Multi-antibiotic-resistant Germs.
A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.
Comparative Clinical Study Between Colistin-Tigecycline Combined Therapy Versus Colistin-Meropenem Combined Therapy in Treatment of Blood Stream Infections With Multidrug-Resistant Klebsiella Pneumoniae
Nebulized Colistin for Gram Negative VAP Prevention.
A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
The Effect of Colistin Inhalation on Ventilator Associated Pneumonia
Efficacy and Mortality of a Loading Dose of Colistin in Critical Ill Patients
Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 32